GRCE

Grace Therapeutics, Inc

Add to Watchlist

Advanced Chart

2.590

+0.030(+1.170%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

2.590

Open

2.560

VWAP

2.57

Vol

18.73K

Mkt Cap

26.28M

Low

2.560

Amount

48.15K

EV/EBITDA(TTM)

Total Shares

10.14M

14.35M

EV/OCF(TTM)

P/S(TTM)

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

2 Analyst Rating

344.02% Upside

Wall Street analysts forecast GRCE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRCE is 11.50 USD with a low forecast of 11.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

344.02% Upside

Current: 2.590

Low

11.00

Averages

11.50

High

12.00

344.02% Upside

Current: 2.590

Low

11.00

Averages

11.50

High

12.00

HC Wainwright & Co.

Oren Livnat

Strong Buy

Reiterates

$12

2025-02-18

Reason

HC Wainwright & Co.

Oren Livnat

Price Target

$12

2025-02-18

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Grace Therapeutics, Inc (GRCE.O) is -2.35, compared to its 5-year average forward P/E of -2.90. For a more detailed relative valuation and DCF analysis to assess Grace Therapeutics, Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.90

Current PE

-2.35

Overvalued PE

-2.40

Undervalued PE

-3.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.16

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.89

Undervalued EV/EBITDA

-1.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00